Introduction: Breast cancer is currently the most prevalent form of cancer in the world. Early stage treatments such as selective estrogen receptor modulators and antibodybased therapies have proven effective, but there are few options for late stage triple-negative disease (TNBC). Thus, current research is focused on chemopreventive and chemotherapeutic agents for late stage disease. Dr. Hansen’s lab has found evidence that their synthesized β-amino alcohol compounds are potential targets for cancer treatments due to their cytotoxic effects on brine shrimp and the HL-60 leukemia cell line. The benzylamine and epoxide product synthesized has an LC50 value of 8.28 uM which indicates that the compound is potentially very cytotoxic at low doses against cancer cells.
Methods: In order to investigate the effects of the benzylamine product on human breast cancer cell lines SUM159 (TNBC) and MCF7 (early stage), I treated the cells with different concentrations of the benzylamine product dissolved in DMSO and cell media and performed a crystal violet assay at 24, 48, 72, and 96 hours to visualize cell viability.
Results: The SUM159 cell viability was decreased in the treated wells in comparison to the control wells, but the results were not significant. In the MCF7 cells, there was significantly lower cell viability in the wells treated with 3uM, 300nM, and 30nM at 48 hours and 3uM at 72 hours compared to the wells treated with DMSO as a vehicle control.
Discussion: My results indicate that the benzylamine product is a potential antitumor drug because of its cytotoxic effects against the SUM159 and MCF7 breast cancer cell lines. Future work will include repetition of this experiment and testing the benzylamine product on other cell lines including a noncancerous cell line.
Hinshaw, Rachael and Mordan-McCombs, Sarah PhD, "Investigating the effects of the benzylamine and epoxide product on the cell viability of MCF7 and SUM159 breast cancer cell lines" (2021). Annual Student Research Poster Session. 68, Scholarly and Creative Work from DePauw University.